AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00891800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Sphere
Description: Brachytherapy Radiation seeds
Study NCT02892253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Camera (NIR)
Description: Surgical field is examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
Study NCT02196766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bioclean First Care EX / comfilcon A
Description: Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
Study NCT03809624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Study NCT03277196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules for oral administration.
Study NCT02196766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aosept Clearcare / comfilcon A
Description: Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
Study NCT02481830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02481830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Study NCT02481830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrubicin
Study NCT03144505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT combined with RT Group
Study NCT03144505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT combined with RT Group
Study NCT01853657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virological monitoring
Study NCT01433497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Study NCT01433497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04188197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL
Description: Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
Study NCT04664556 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: observational study
Study NCT01350557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Description: Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
Study NCT01350557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subacute care
Description: Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
Study NCT00794456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Passiflora ; Crataegus and Salix
Description: 1 tablet PO twice a day
Study NCT00794456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valeriana
Description: 1 tablet PO twice a day
Study NCT00770822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU (Sonablate® 500)
Description: High Intensity Focused Ultrasound
Study NCT00770822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Standard of care
Study NCT02543632 — intervention group
Intervention type: DEVICE
Intervention: Parachute Implant System
Description: The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
Study NCT01356693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelin
Description: Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
Study NCT01356693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with mimicking characteristics of experimental drug
Study NCT01294917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-purpose disinfecting solution
Description: For the cleaning, rinsing, and storage of soft contact lenses.
Study NCT01294917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care
Description: Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
Study NCT01294917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free RepleniSH
Description: Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
Study NCT01838135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WheelSeeU Training Program
Description: WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
Study NCT03135886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information Control
Description: The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
Study NCT03135886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV and HCV Testing Practice Coaching Intervention
Description: The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).
Study NCT03135886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Testing Practice Coaching Intervention
Description: The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
Study NCT03906825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CEAG
Description: Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA
Study NCT03906825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00486486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: bimatoprost/timolol fixed combination AM
Description: 3-month chronic dosing in the morning
Study NCT00486486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost/timolol fixed combination dosed PM
Description: Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
Study NCT02299193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
Study NCT02299193 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healthy Sleep Habits
Description: 6 weekly, 20 minute online sessions about healthy sleep practices
Study NCT04217343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Allosure/Allomap/Cytokines testing
Description: All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
Study NCT03757598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePartogram use
Description: Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
Study NCT00371267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-delivered Cognitive Behavior Therapy
Description: Telephone-delivered cognitive behavior therapy for pain management
Study NCT00371267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-delivered Patient Education
Description: Telephone-delivered patient education regarding chronic pain
Study NCT03404362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Metastases Pain treatment
Description: Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
Study NCT01784887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procellera
Description: PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
Study NCT02473796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based child care
Description: HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight \<2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term \& weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
Study NCT00896961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Study NCT02811666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of sarcopenia by CT-Scan
Study NCT02811666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand gauge
Study NCT03021018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/ml~* Route of Administration: intravenous
Study NCT03021018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: * Pharmaceutical Form: Solution for injection~* Route of Administration: intravenous
Study NCT00132262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention based on motivational interviewing
Description: The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
Study NCT00132262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care including referral for treatment
Description: Standard hospital care provided the patient with information and referral for treatment as necessary.
Study NCT04609722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solution-Focused Support Program
Description: All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
Study NCT01904344 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sensor testing and validation
Study NCT04543760 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prone position
Description: prone positioning in spontaneous ventilation
Study NCT04543760 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supine position
Description: supine positiong in spontaneous ventilation
Study NCT02282189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oscillating Positive Expiratory Pressure (Aerobika ®)
Description: The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
Study NCT01635322 — intervention group
Intervention type: DEVICE
Intervention: Polyaxial posterior spinal fusion system
Description: posterior correction and fusion of the thoraco-lumbar or lumbar spine
Study NCT03633474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N. lactamica
Description: Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
Study NCT03633474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PBS only
Description: Sterile PBS only containing no bacteria
Study NCT04525365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pleural aspiration
Description: Pleural aspiration
Study NCT04525365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleural aspiration
Description: Pleural aspiration
Study NCT03961230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin granules
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Study NCT03961230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jueyin Granules Placebo
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Study NCT01900626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: epidural catheter with 0.3% ropivacaine
Study NCT03611374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae Plane Block (ESPB)
Description: Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
Study NCT00845715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early motion
Description: Early referral to physical therapy for range of motion (2 days post)
Study NCT00845715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard motion
Description: Standard referral to physical therapy for range of motion (4 weeks post)
Study NCT01692717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg
Study NCT04555148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC5131
Description: COVID19 Hyper-Immunoglobulin
Study NCT01692717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg
Study NCT01692717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide + Losartan
Description: 12.5 mg + 50 mg
Study NCT01692717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Losartan
Description: 12.5 mg + 50 mg
Study NCT01692717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide + Losartan + Atorvastatin
Description: 12.5 mg + 50 mg + 10 mg
Study NCT01692717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Losartan + Atorvastatin
Description: 12.5 mg + 50 mg + 10 mg
Study NCT02612298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arotinolol Hydrochloride
Description: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
Study NCT02612298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate sustained-release tablet
Description: Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
Study NCT00989274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Sanofi A(H1N1) 15 ug & trivalent
Description: Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
Study NCT00989274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Sanofi (H1N1) 15 ug.nonadyuvante
Description: Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
Study NCT00989274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Sanofi A(H1N1) 7.5 ug
Description: Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
Study NCT01519661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBM100
Description: Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
Study NCT03918174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dart splint orthosis
Description: The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.
Study NCT03918174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.